Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HYDEN, KY · NPI 1538149596
Verified facts
CMS Open Payments records show Brian S Overbee, FNP received $23.35 in general payments during 2025 across 1 reported records.
Madrigal Pharmaceuticals accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $23.35 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $23.35 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $23.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pravastatin Sodium | Pravastatin Sodium | 319 | 81 |
| Gabapentin | Gabapentin | 275 | 41 |
| Lisinopril | Lisinopril | 226 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 51 |
| Fluconazole | Fluconazole | 192 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 45 |
| Famotidine | Famotidine | 176 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 170 | 50 |
| Buspirone Hcl | Buspirone Hcl | 156 | 46 |
| Glipizide | Glipizide | 153 | 35 |
| Metformin Hcl | Metformin Hcl | 153 | 39 |
| Montelukast Sodium | Montelukast Sodium | 150 | 38 |
| Omeprazole | Omeprazole | 133 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 42 |
| Azithromycin | Azithromycin | 129 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 127 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 39 |
| Potassium Chloride | Potassium Chloride | 124 | 38 |
| Baclofen | Baclofen | 120 | 51 |
| Losartan Potassium | Losartan Potassium | 120 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 31 |
| Tramadol Hcl | Tramadol Hcl | 101 | 20 |
| Furosemide | Furosemide | 94 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 14 |
| Methylprednisolone | Methylprednisolone | 83 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 22 |
| Trazodone Hcl | Trazodone Hcl | 76 | 21 |
| Amoxicillin | Amoxicillin | 75 | 49 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 73 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 18 |
| Januvia | Sitagliptin Phosphate | 71 | 13 |
| Allopurinol | Allopurinol | 68 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 49 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 66 | 24 |
| Nystatin | Nystatin | 66 | 23 |
| Ofloxacin | Ofloxacin | 66 | 46 |
| Cefdinir | Cefdinir | 65 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 64 | 20 |
| Levetiracetam | Levetiracetam | 61 | 13 |
| Clonidine Hcl | Clonidine Hcl | 58 | 11 |
| Meclizine Hcl | Meclizine Hcl | 54 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 54 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 15 |
| Mupirocin | Mupirocin | 45 | 29 |
| Meloxicam | Meloxicam | 44 | 14 |
| Sertraline Hcl | Sertraline Hcl | 44 | 14 |
| Ibuprofen | Ibuprofen | 43 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 13 |
| Ozempic | Semaglutide | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | 13 |
| Vascepa | Icosapent Ethyl | 42 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 15 |
| Ibu | Ibuprofen | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 19 |
| Atenolol | Atenolol | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 13 |
| Cephalexin | Cephalexin | 32 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 29 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Lidocaine | Lidocaine | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23.35 · 1 records | Madrigal Pharmaceuticals | REZDIFFRA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error